Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European Urology

• Publication date

  2011-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.eururo.2011.05.035PMID 21640482
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of anti-Her-2 therapy in bladder carcinoma

  2010cited by this paper
• Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis

  2010cited by this paper
• Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients

  2009cited by this paper
• Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.

  2009cited by this paper
• TNM Classification of Malignant Tumours, 7th Edition

  2009cited by this paper
• HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases.

  2008cited by this paper
• Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.

  2008cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

  2007cited by this paper
• Trastuzumab--mechanism of action and use in clinical practice.

  2007cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Systemic chemotherapy for advanced bladder cancer: update and controversies.

  2006cited by this paper
• Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.

  2005cited by this paper
• Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor.

  2005cited by this paper
• Change of HER‐2/neu status in a subset of distant metastases from breast carcinomas

  2004cited by this paper
• HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?

  2004cited by this paper
• HER-2 testing in breast cancer using parallel tissue-based methods.

  2004cited by this paper
• HER‐2 and TOP2A coamplification in urinary bladder cancer

  2003cited by this paper
• Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

  2001cited by this paper
• Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors.

  2001cited by this paper
• Tissue microarrays for high-throughput molecular profiling of tumor specimens

  1998cited by this paper
• Experience in 100 patients with an ileal low pressure bladder substitute combined with an afferent tubular isoperistaltic segment.

  1995cited by this paper
• c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.

  1991cited by this paper

• p16 positivity as a potent indicator of high-grade histology and its interplay with HER2/neu in urothelial bladder carcinoma.

  2026cites this paper
• B2B: Bladder Cancer Summary

  2026cites this paper
• Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48

  2025cites this paper
• The bladder cancer m6A landscape is defined by methylation dilution and 3′-UTR hypermethylation

  2025influential citation
• Antibody-Drug Conjugates in Urothelial, Prostate, and Renal Cell Cancers: A Review of Current and Emerging Therapies.

  2025cites this paper
• Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy

  2025cites this paper
• Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies

  2025cites this paper
• Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer

  2025cites this paper
• Emerging Biomarkers in Bladder Cancer: Translating Molecular Advances into Precision Oncology.

  2025cites this paper
• Human epidermal growth factor receptor 2 overexpression is associated with high-grade tumors in upper tract urothelial carcinoma

  2025cites this paper
• HER2/neu as a Signaling and Therapeutic Marker in Uterine Serous Carcinoma

  2025cites this paper
• HER2-Positive Urothelial Carcinoma: Current Evidence on Targeted Agents and Immunotherapy-Based Combinations

  2025influential citation
• ERBB2/HER2 alterations in ctDNA and metachronous tissues of patients with metastatic urothelial cancer.

  2025cites this paper
• A Narrative Review of Current Advances and Future Changes Regarding Bladder Cancer Treatment

  2025cites this paper
• Spatial expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and metastases: Implications for pathological and clinical management.

  2025cites this paper
• An Immunohistochemical Study in Urothelial Carcinoma of HER2/neu in Iraqi Patients

  2025cites this paper
• HER2 and urothelial carcinoma: current understanding and future directions

  2025cites this paper
• Molecular Pathology of Urothelial Carcinoma.

  2024cites this paper
• Clinical significance of HER2 in urothelial carcinoma and analysis of its correlation with glycolytic metabolic characteristics

  2024cites this paper
• Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer

  2024cites this paper
• Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives

  2024cites this paper
• Basic Study on Gene Biology of Bladder Cancer Metastasis

  2024cites this paper
• Performance of a HER2 testing algorithm tailored for urothelial bladder cancer: A Bi-centre study

  2024cites this paper
• Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

  2024cites this paper
• Contemporary Molecular Markers for Predicting Systemic Treatment Response in Urothelial Bladder Cancer: A Narrative Review

  2024cites this paper
• Prediction of HER2 Status Based on Deep Learning in H&E-Stained Histopathology Images of Bladder Cancer

  2024cites this paper
• Multiparametric MR characterization for human epithelial growth factor receptor 2 expression in bladder cancer: an exploratory study

  2024cites this paper
• Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?

  2024cites this paper
• Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma

  2024cites this paper
• Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer

  2024influential citation
• Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma

  2024cites this paper
• Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma

  2024cites this paper
• MRI‐Based Machine Learning Radiomics for Preoperative Assessment of Human Epidermal Growth Factor Receptor 2 Status in Urothelial Bladder Carcinoma

  2024cites this paper
• Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers

  2024cites this paper
• HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role

  2023cites this paper
• Advances in HER2-Targeted Treatment for Advanced/Metastatic Urothelial Carcinoma

  2023influential citation
• Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study

  2023cites this paper
• Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials

  2023cites this paper
• Real‐world effectiveness and safety of RC48‐ADC alone or in combination with PD‐1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study

  2023cites this paper
• HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: a retrospective cohort study

  2023cites this paper
• Systemic Metastasis of Pediatric Diffuse High-grade Astrocytoma: A Case Report

  2023cites this paper
• Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center’s real-world study

  2023cites this paper
• Expression of epidermal growth factor receptor and human epidermal growth factor receptor 2 in urothelial bladder carcinoma in an Egyptian cohort: Clinical implication and prognostic significance

  2023cites this paper
• Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18

  2023cites this paper
• Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival

  2023cites this paper
• Antibody–Drug Conjugates in the Treatment of Urothelial Cancer

  2023cites this paper
• Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers

  2023cites this paper
• Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma

  2023cites this paper
• Precision Medicine in Bladder Cancer: Present Challenges and Future Directions

  2023cites this paper
• HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population

  2023cites this paper
• Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates

  2022cites this paper
• HER2 expression in urothelial carcinoma, a systematic literature review

  2022influential citation
• Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: A retrospective single‑center experience

  2022cites this paper
• An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next

  2022cites this paper
• Disseminierte Tumorzellen beim Harnblasenkarzinom

  2022cites this paper
• A novel strategy for treatment of bladder cancer: Antibody-drug conjugates

  2022cites this paper
• Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy

  2022cites this paper
• Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants

  2022cites this paper
• Clinicopathological Review of Micropapillary Urothelial Carcinoma

  2022cites this paper
• The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives.

  2022cites this paper
• A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin.

  2021cites this paper
• Molecular Pathology

  2021cites this paper
• Molecular Pathology of Urothelial Carcinoma.

  2021cites this paper
• Proteomics as a Complementary Technique to Characterize Bladder Cancer

  2021cites this paper
• Risk Stratification of Patients: Risk Tables and Assessment – NMIBC and MIBC

  2021cites this paper
• Lymphatic metastasis of bladder cancer: Molecular mechanisms, diagnosis and targeted therapy.

  2021cites this paper
• The Clinical Significance and Prognostic Value of HER2 Expression in Bladder Cancer: A Meta-Analysis and a Bioinformatic Analysis

  2021cites this paper
• Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer

  2021cites this paper
• Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity

  2021cites this paper
• Demethoxycurcumin induces apoptosis in HER2 overexpressing bladder cancer cells through degradation of HER2 and inhibiting the PI3K/Akt pathway

  2021cites this paper
• Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy—A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin

  2021cites this paper
• Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer

  2021cites this paper
• Evaluation of HER2/neu and SPINK1 as an adjunct to the prognosis of urothelial dysplasia and urothelial carcinoma of the urinary bladder

  2021cites this paper
• Developing Precision Medicine for Bladder Cancer.

  2021cites this paper
• HER-2 overexpression is a negative predictive factor for recurrence in patients with non-muscle-invasive bladder cancer on intravesical therapy

  2020cites this paper
• Targeted Therapy in Metastatic Bladder Cancer: Present Status and Future Directions

  2020cites this paper
• Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications

  2020cites this paper
• Role of tyrosine kinases in bladder cancer progression: an overview

  2020cites this paper
• Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

  2020cites this paper
• Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells

  2020cites this paper
• Survivin and Her2 Expressions in Different Grades of Urothelial Neoplasms of Urinary Bladder

  2020cites this paper
• The Clinical Signi cance and Prognostic Value of HER2 Expression in Bladder Cancer: a Systematic Review and Meta-analysis

  2020cites this paper
• Combination of histological and molecular data for improving outcome prediction in non-muscle invasive bladder cancer—narrative review

  2020cites this paper
• Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

  2020cites this paper
• Updates on the Genomics of Bladder Cancer and Novel Molecular Taxonomy

  2019cites this paper
• The current role of circulating biomarkers in non-muscle invasive bladder cancer

  2019cites this paper
• Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.

  2019cites this paper
• Investigating the Levels of Shed Extracellular Domain of HER2 Protein in the Sera of Bladder Cancer Patients

  2019cites this paper
• Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?

  2019cites this paper
• Management of metastatic bladder cancer.

  2019cites this paper
• Exosomes containing ErbB2/CRK induce vascular growth in premetastatic niches and promote metastasis of bladder cancer

  2019cites this paper
• Robot-assisted pelvic lymphadenectomy for prostate cancer . Potentially advantageous in the elderly ?

  2019cites this paper
• PLAC8 overexpression correlates with PD-L1 upregulation and acquired resistance to chemotherapies in gallbladder carcinoma.

  2019cites this paper
• Micropapillary Carcinoma of the Bladder: Recent Advances

  2019cites this paper
• Molecular/ Genetic/ Protein Characterizing of Bladder Cancer Circulating Tumor Cells

  2019cites this paper
• Somatic copy number aberrations in metastatic patients: The promise of liquid biopsies.

  2019cites this paper
• HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter.

  2019cites this paper
• Updates on the Genetics and Molecular Subtypes of Urothelial Carcinoma and Select Variants.

  2018cites this paper
• Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

  2018cites this paper
• Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases

  2018cites this paper